Primary diffuse large B-cell lymphoma of the prostate: a case report and review of the literature

par Mengwei Ren, Yanli Liu
Publié 2021

Epstein-Barr Virus-Positive Adrenal Diffuse Large B-Cell Lymphoma after Treatment for Angioimmunoblastic T-Cell Lymphoma

par Akiko Hashimoto, Satsuki Asai, Yasuhiro Tanaka, Isaku Shinzato
Publié 2021

More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Fea...

par Lucijanic M, Huzjan Korunic R, Sedinic M, Kusec R, Pejsa V
Publié 2021

The Dark Side of Pyroptosis of Diffuse Large B-Cell Lymphoma in B-Cell Non-Hodgkin Lymphoma: Mediating the Specific Inflammatory Microenvironment

par Wei Wang, Shi-wen Xu, Ya Teng, Min Zhu, Qun-yi Guo, Qun-yi Guo, Yuan-wen Wang, Yuan-wen Wang, Xin-Li Mao, Xin-Li Mao, Xin-Li Mao, Shao-wei Li, Shao-wei Li, Shao-wei Li, Wen-da Luo, Wen-da Luo, Wen-da Luo
Publié 2021

Integrated bioinformatics analysis reveals dynamic candidate genes and signaling pathways involved in the progression and prognosis of diffuse large B-cell lymphoma

par Alice Charwudzi, Ye Meng, Linhui Hu, Chen Ding, Lianfang Pu, Qian Li, Mengling Xu, Zhimin Zhai, Shudao Xiong
Publié 2021

Antibody Therapies for Large B-Cell Lymphoma

par Novo M, Santambrogio E, Frascione PMM, Rota-Scalabrini D, Vitolo U
Publié 2021

A Cohort Study of the Prognostic Impact of Exon-16 EZH2 Mutations in a Mexican-Mestizo Population of Patients with Diffuse Large B-Cell Lymphoma

par Luis F. Oñate-Ocaña, Mayra Ponce-Martínez, Lucia Taja-Chayeb, Olga Gutiérrez-Hernández, Alejandro Avilés-Salas, David Cantú-de-León, Alfonso Dueñas-González, Myrna Candelaria-Hernández
Publié 2021

The Value of Prognostic Nutritional Index (PNI) on Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: A Multicenter Retrospective Study of HHLWG Based on Propensity Score Matc...

par Shen Z, Wang F, He C, Li D, Nie S, Bian Z, Yao M, Xue Y, Wang Y, Gu W, Zhu T, Shi Y, Zhang H, Huang S, Miao Y, Sang W
Publié 2021

Efficacy and Safety of Lenalidomide Monotherapy for Relapsed/Refractory Diffuse Large B Cell Lymphoma: Systematic Review and Meta-Analysis

par Jia Li, Jianpeng Zhou, Wei Guo, Xingtong Wang, Yangzhi Zhao, Ou Bai
Publié 2021

Excess Mortality by Multimorbidity, Socioeconomic, and Healthcare Factors, amongst Patients Diagnosed with Diffuse Large B-Cell or Follicular Lymphoma in England

par Matthew James Smith, Aurélien Belot, Matteo Quartagno, Miguel Angel Luque Fernandez, Audrey Bonaventure, Susan Gachau, Sara Benitez Majano, Bernard Rachet, Edmund Njeru Njagi
Publié 2021

Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: A single-center experience.

par Kanta Devi, Muhammad Usman Shaikh, Natasha Bahadur Ali, Salman Naseem Adil, Maria Khan, Salman Muhammad Soomar
Publié 2021

Impact of Cell-of-Origin on Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Uniform R-CHOP Protocol: A Single-Center Retrospective Analysis From North India

par Ajay Gogia, Sukesh Nair, Shalabh Arora, Lalit Kumar, Atul Sharma, Ritu Gupta, Ahitagni Biswas, Saumyaranjan Mallick
Publié 2021

Proteomic Profiling Differentiates Lymphoma Patients with and without Concurrent Myeloproliferative Neoplasia

par Johanne Marie Holst, Marie Beck Enemark, Martin Bjerregaard Pedersen, Kristina Lystlund Lauridsen, Trine Engelbrecht Hybel, Michael Roost Clausen, Henrik Frederiksen, Michael Boe Møller, Peter Nørgaard, Trine Lindhardt Plesner, Stephen Jacques Hamilton-Dutoit, Francesco d’Amore, Bent Honoré, Maja Ludvigsen
Publié 2021

Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience

par Schaefer A, Huang Y, Kittai A, Maakaron JE, Saygin C, Brammer J, Penza S, Saad A, Jaglowski SM, William BM
Publié 2021

CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL)

par Guido Gini, Alice Di Rocco, Luca Nassi, Annalisa Arcari, Maria Chiara Tisi, Giacomo Loseto, Attilio Olivieri, Massimo Gentile, Ombretta Annibali, Maria Giuseppina Cabras, Annalisa Chiappella, Chiara Rusconi, Andrés José María Ferreri, Monica Balzarotti
Publié 2021

Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review

par Chao Chen, Wei Zhang, Daobin Zhou, Yan Zhang
Publié 2021

Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP re...

par Zhang F, Li L, Zhang L, Li X, Fu X, Wang X, Wu J, Sun Z, Kong F, Ren L, Zhang M
Publié 2019

Epigenetic Regulation of miR-92a and TET2 and Their Association in Non-Hodgkin Lymphoma

par Esther K. Elliott, Esther K. Elliott, Lloyd N. Hopkins, Robert Hensen, Heidi G. Sutherland, Larisa M. Haupt, Lyn R. Griffiths
Publié 2021

ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma

par Giulio Sartori, Sara Napoli, Luciano Cascione, Elaine Yee Lin Chung, Valdemar Priebe, Alberto Jesus Arribas, Afua Adjeiwaa Mensah, Michela Dall’Angelo, Chiara Falzarano, Laura Barnabei, Mattia Forcato, Andrea Rinaldi, Silvio Bicciato, Margot Thome, Francesco Bertoni
Publié 2021

Efficacy and Safety of Innovative Experimental Chimeric Antigen Receptor (CAR) T-cells versus Axicabtagene ciloleucel (Yescarta) for the Treatment of Relapsed/Refractory Large B-Ce...

par Bayarmagnai Weinstein, Bogdan Muresan, Sara Solano, Antonio Vaz de Macedo, YoonJung Lee, Yu-Chen Su, Yeseul Ahn, Gabriela Henriquez, Christina Carmago, Gwang-Jin Kim, David O. Carpenter
Publié 2021